The DOI matches its Crossref record; 394 of the 394 references it cites were found in a registry or an index.
Genetics and biology of pancreatic ductal adenocarcinoma
Open accessAbstract
With 5-year survival rates remaining constant at 6% and rising incidences associated with an epidemic in obesity and metabolic syndrome, pancreatic ductal adenocarcinoma (PDAC) is on track to become the second most common cause of cancer-related deaths by 2030. The high mortality rate of PDAC stems primarily from the lack of early diagnosis and ineffective treatment for advanced tumors. During the past decade, the comprehensive atlas of genomic alterations, the prominence of specific pathways, the preclinical validation of such emerging targets, sophisticated preclinical model systems, and the molecular classification of PDAC into specific disease subtypes have all converged to illuminate drug discovery programs with clearer clinical path hypotheses. A deeper understanding of cancer cell biology, particularly altered cancer cell metabolism and impaired DNA repair processes, is providing novel therapeutic strategies that show strong preclinical activity. Elucidation of tumor biology principles, most notably a deeper understanding of the complexity of immune regulation in the tumor microenvironment, has provided an exciting framework to reawaken the immune system to attack PDAC cancer cells. While the long road of translation lies ahead, the path to meaningful clinical progress has never been clearer to improve PDAC patient survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the mutational frequency data combined with the observation from the simulations suggest that at least in the pancreatic cancer, where a KRAS mutation is a key initiator [68], a major shift in KRAS dynamics is not tolerated.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712
The chemokine system in diverse forms of macrophage activation and polarization
MANTOVANI, A., SICA, A., SOZZANI, S., ALLAVENA, P., VECCHI, A., & LOCATI, M. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.09.015 · Cited by 6,534
MANTOVANI, A., SOZZANI, S., LOCATI, M., ALLAVENA, P., & SICA, A. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(02)02302-5 · Cited by 5,528
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Research works printed but not linked: 1
- Kloppel G . 2000. WHO classification of tumours. IARC Press, Lyon, France.
Cited by
Sorted by citations
Items 101–200 of 533
Pergolini, I., Morales‐Oyarvide, V., Mino-Kenudson, M. A., Honselmann, K. C., Rosenbaum, M. W., Nahar, S., Kem, M., Ferrone, C. R., Lillemoe, K. D., Bardeesy, N. M., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182855 · Cited by 65
Klett, H., Füllgraf, H., Levit‐Zerdoun, E., Hussung, S., Kowar, S., Küsters, S., Bronsert, P., Werner, M., Wittel, U. A., Fritsch, R., et al. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00108 · Cited by 62
Tsai, P.-Y., Lee, M.-S., Jadhav, U., Naqvi, I., Madha, S., Adler, A., Mistry, M., Naumenko, S., Lewis, C. A., Hitchcock, D. S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003014118 · Cited by 67
Cai, X., Ding, H., Liu, Y., Pan, G., Li, Q., Yang, Z., & Liu, W. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw124 · Cited by 62
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma
Windon, A. L., Loaiza‐Bonilla, A., Jensen, C. E., Randall, M. P., Morrissette, J. J. D., & Shroff, S. G. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2017.10.14 · Cited by 61
Deciphering DNA methylation signatures of pancreatic cancer and pancreatitis
Natale, F., Vivo, M., Falco, G., & Angrisano, T. (2019) · Clinical Epigenetics · doi:10.1186/s13148-019-0728-8 · Cited by 64
Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight
Cortesi, M., Zanoni, M., Pirini, F., Tumedei, M. M., Ravaioli, S., Rapposelli, I. G., Frassineti, G. L., & Bravaccini, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010254 · Cited by 62
Hao, F., Xu, Q., Wang, J., Yu, S., Chang, H.-H., Sinnett-Smith, J., Eibl, G., & Rozengurt, E. (2019) · PLOS ONE · doi:10.1371/journal.pone.0216603 · Cited by 55
Donahue, K. L., Watkoske, H. R., Kadiyala, P., Du, W., Brown, K. L., Scales, M. K., Elhossiny, A. M., Espinoza, C. E., Opsahl, E. L. L., Griffith, B. D., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0100 · Cited by 60
Knudsen, E. S., Balaji, U., Freinkman, E., McCue, P. A., & Witkiewicz, A. K. (2016) · Oncotarget · doi:10.18632/oncotarget.11893 · Cited by 61
Jiang, S., Zhu, L., Yang, J., Hu, L.-P., Gu, J., Xing, X., Sun, Y., & Zhang, Z. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.10.072 · Cited by 61
For and against tumor microenvironment: Nanoparticle-based strategies for active cancer therapy
Karimi, S., Bakhshali, R., Bolandi, S., Zahed, Z., Zadeh, S. S. M., Zenjanab, M. K., & Jahanban‐Esfahlan, R. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101626 · Cited by 60
Acinar cell clonal expansion in pancreas homeostasis and carcinogenesis
Neuhöfer, P., Roake, C. M., Kim, S. J., Lu, R. J., West, R. B., Charville, G. W., & Artandi, S. E. (2021) · Nature · doi:10.1038/s41586-021-03916-2 · Cited by 60
Islam, S., Kitagawa, T., Baron, B., Abiko, Y., Chiba, I., & Kuramitsu, Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-90077-x · Cited by 55
Wolfe, A. L., Zhou, Q., Toska, E., Galeas, J., Ku, A. A., Koche, R. P., Bandyopadhyay, S., Scaltriti, M., Lebrilla, C. B., McCormick, F. P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2103592118 · Cited by 55
Sharib, J. M., Fonseca, A. L., Swords, D. S., Jaradeh, K., Bracci, P. M., Firpo, M. A., Hatcher, S., Scaife, C. L., Wang, H., Kim, G. E., et al. (2018) · Surgery · doi:10.1016/j.surg.2018.07.014 · Cited by 55
Abbruzzese, J. L., Andersen, D. K., Borrebaeck, C. A. K., Chari, S. T., Costello, E., Cruz‐Monserrate, Z., Eibl, G., Engleman, E. G., Fisher, W. E., Habtezion, A., et al. (2018) · Pancreas · doi:10.1097/mpa.0000000000001037 · Cited by 57
ARID1A in cancer: Friend or foe?
Fontana, B., Gallerani, G., Salamon, I., Pace, I., Roncarati, R., & Ferracin, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1136248 · Cited by 58
Lam, B., Shrivastava, S. K., Shrivastava, A., Shankar, S., & Srivastava, R. K. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15413 · Cited by 53
Multifaceted role for p53 in pancreatic cancer suppression
Mello, S. S., Flowers, B. M., Mazur, P. K., Lee, J. J., Müller, F., Denny, S. K., Ferreira, S., Hanson, K., Kim, S. K., Greenleaf, W. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2211937120 · Cited by 55
Shen, J., Ha, D. P., Zhu, G., Rangel, D. F., Kobielak, A., Gill, P. S., Groshen, S. G., Dubeau, L., & Lee, A. S. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1616060114 · Cited by 53
Yang, J., Jin, L., Kim, H. S., Tian, F., Yi, Z., Bedi, K., Ljungman, M. E., di Magliano, M. P., Crawford, H. C., & Shi, J. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0968 · Cited by 55
Epithelial-Myeloid cell crosstalk regulates acinar cell plasticity and pancreatic remodeling in mice
Zhang, Y., Yan, W., Mathew, E., Kane, K. T., Brannon, A., Adoumie, M., Vinta, A., Crawford, H. C., & di Magliano, M. P. (2017) · eLife · doi:10.7554/elife.27388 · Cited by 55
SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer
Zhou, H., Qin, Y., Ji, S., Ling, J., Fu, J., Zhuang, Z., Fan, X., Song, L., Yu, X., & Chiao, P. J. (2017) · Oncogene · doi:10.1038/onc.2017.393 · Cited by 52
Extracellular Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer
Veenstra, V. L., García-Garijo, A., van Laarhoven, H. W. M., & Bijlsma, M. F. (2018) · Cancers · doi:10.3390/cancers10020034 · Cited by 54
Epigenetic Alterations in Pancreatic Cancer Metastasis
Wang, S. S., Xu, J., Ji, K. Y., & Hwang, C. (2021) · Biomolecules · doi:10.3390/biom11081082 · Cited by 50
Huang, H., Sung, Y., Li, C., Wan, D., Chao, P., Tseng, Y., Liao, B.-W., Cheng, H., Hsu, F., Huang, C., et al. (2021) · Gut · doi:10.1136/gutjnl-2021-325180 · Cited by 51
Yan, W., Menjivar, R. E., Bonilla, M. E., Steele, N. G., Kemp, S. B., Du, W., Donahue, K. L., Brown, K. L., Carpenter, E. S., Avritt, F. R., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0037 · Cited by 52
Role of the Tumor Microenvironment in Regulating Pancreatic Cancer Therapy Resistance
Deng, D., Patel, R. H., Chiang, C.-Y., & Hou, P. (2022) · Cells · doi:10.3390/cells11192952 · Cited by 53
Metformin: review of epidemiology and mechanisms of action in pancreatic cancer
Eibl, G., & Rozengurt, E. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09977-z · Cited by 51
Epithelial-Stromal Interactions in Pancreatic Cancer
Zhang, Y., Crawford, H. C., & di Magliano, M. P. (2018) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114515 · Cited by 52
Pancreatic Fibroblast Heterogeneity: From Development to Cancer
Garcia, P. E., Scales, M. K., Allen, B. L., & di Magliano, M. P. (2020) · Cells · doi:10.3390/cells9112464 · Cited by 48
Targeting the Metabolic Rewiring in Pancreatic Cancer and Its Tumor Microenvironment
Yamamoto, K., Iwadate, D., Kato, H., Nakai, Y., Tateishi, K., & Fujishiro, M. (2022) · Cancers · doi:10.3390/cancers14184351 · Cited by 52
Chawla, A. T., Chougoni, K. K., Joshi, P. J., Cororaton, A. D., Memari, P., Stansfield, J. C., Park, H., Seth, R., Szomju, B. B., Sima, A. P., et al. (2019) · Oncogenesis · doi:10.1038/s41389-019-0163-x · Cited by 47
Redox tolerance and metabolic reprogramming in solid tumors
Mortezaee, K. (2020) · Cell Biology International · doi:10.1002/cbin.11506 · Cited by 48
Yu, T., Li, G., Wang, C., Gong, G., Wang, L., Li, C., Chen, Y., & Wang, X. (2021) · RNA Biology · doi:10.1080/15476286.2021.1930755 · Cited by 47
Genetic Alterations of Periampullary and Pancreatic Ductal Adenocarcinoma: An Overview
Sikdar, N., Saha, G., Dutta, A., Ghosh, S., Shrikhande, S. V., & Banerjee, S. (2018) · Current Genomics · doi:10.2174/1389202919666180221160753 · Cited by 51
Biondani, G., Zeeberg, K., Greco, M. R., Cannone, S., Dando, I., Pozza, E. D., Mastrodonato, M., Forciniti, S., Casavola, V., Palmieri, M., et al. (2018) · FEBS Journal · doi:10.1111/febs.14471 · Cited by 47
Frappart, P., & Hofmann, T. G. (2020) · Cancers · doi:10.3390/cancers12102750 · Cited by 48
Fibroblast Growth Factor 10 in Pancreas Development and Pancreatic Cancer
Ndlovu, R., Deng, L., Wu, J., Li, X., & Zhang, J. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00482 · Cited by 46
Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy
Aziz, A., Rehman, U., Sheikh, A., Abourehab, M. A. S., & Kesharwani, P. (2022) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2022.2121592 · Cited by 47
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies
Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 49
Tu, M., Pan, Y.-Z., Qiu, J.-X., Kim, E. J.-H., & Yu, A. (2016) · Oncotarget · doi:10.18632/oncotarget.9999 · Cited by 44
Singh, K., Pruski, M. A., Bland, R., Younes, M., Guha, S., Thosani, N. C., Maitra, A., Cash, B. D., McAllister, F. M., Logsdon, C. D., et al. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-00490-5 · Cited by 43
Abd-El-Halim, Y. M., Kaoutari, A. E., Silvy, F., Rubis, M., Bigonnet, M., Roques, J., Cros, J. F., Nicolle, R., Iovanna, J., Dusetti, N., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103541 · Cited by 44
Discovery of the Highly Selective and Potent STAT3 Inhibitor for Pancreatic Cancer Treatment
Huang, C., Bian, A., Zhou, W., Miao, Y., Ye, J., Li, J., He, P., Zhang, Q., Sun, Y., Sun, Z., et al. (2024) · ACS Central Science · doi:10.1021/acscentsci.3c01440 · Cited by 45
Liu, Y., Han, J., Hsu, W., LaBella, K. A., Deng, P., Shang, X., de Lara, P. T., Cai, L., Jiang, S., & DePinho, R. A. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0489 · Cited by 43
Collet, L., Ghurburrun, E., Meyers, N., Assi, M., Pirlot, B., Leclercq, I. A., Couvelard, A., Komuta, M., Cros, J. F., Demetter, P., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318059 · Cited by 43
Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules
Singh, K., Lin, J., Lecomte, N., Mohan, P., Gokce, A., Sanghvi, V. R., Jiang, M., Grbovic-Huezo, O., Burčul, A., Stark, S. G., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2929 · Cited by 39
TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery
Xiang, S., Song, S., Tang, H., Smaill, J. B., Wang, A., Xie, H., & Lu, X. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.05.016 · Cited by 41
Pancreatic Cancer: “A Riddle Wrapped in a Mystery inside an Enigma”
Borazanci, E. H., Dang, C. V., Robey, R. W., Bates, S. E., Chabot, J. A., & Hoff, D. D. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2070 · Cited by 42
Gupta, N., & Yelamanchi, R. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i23.3158 · Cited by 47
Cui, X., Wang, Y., Lan, W., Wang, S., Cui, Y. J., Zhang, X., Lin, Z., & Piao, J. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00652-7 · Cited by 40
Ideno, N., Yamaguchi, H., Okumura, T., Huang, J., Brun, M. J., Ho, M., Suh, J., Gupta, S., Maitra, A., & Ghosh, B. (2018) · bioRxiv · doi:10.1038/s41374-018-0171-z · Cited by 38
Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.09.001 · Cited by 39
Energy sources identify metabolic phenotypes in pancreatic cancer
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmw097 · Cited by 37
Liang, C., Shi, S., Meng, Q., Liang, D., Ji, S., Zhang, B., Qin, Y., Xu, J., Ni, Q., & Yu, X. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2678-7 · Cited by 39
Qiu, W., Duan, N., Chen, X., Ren, S., Zhang, Y., Wang, Z., & Chen, R. (2019) · Cancer Management and Research · doi:10.2147/cmar.s218414 · Cited by 39
Insight into the mechanism of allosteric activation of PI3Kα by oncoprotein K-Ras4B
Li, X., Dai, J., Ni, D., He, X., Zhang, H., Zhang, J., Fu, Q., Liu, Y., & Lu, S. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.020 · Cited by 39
Molecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
Espiau-Romera, P., Courtois, S., Parejo-Alonso, B., & Sancho, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124128 · Cited by 43
Song, B. G., Kwon, W., Kim, H. M., Lee, E. M., Han, Y. M., Kim, H., Byun, Y., Lee, K. B., Lee, K. H., Lee, K. T., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.616440 · Cited by 39
Multifaced roles of PLAC8 in cancer
Mao, M., Cheng, Y., Yang, J., Chen, Y., Xu, L., Zhang, X., Li, Z., Chen, C., Ju, S., Zhou, J., et al. (2021) · Biomarker Research · doi:10.1186/s40364-021-00329-1 · Cited by 38
Wu, J., Wang, X., Chen, L., Wang, J., Zhang, J., Tang, J., Ji, Y., Song, J., Wang, L., Zhao, Y., et al. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.05.022 · Cited by 38
Yin, X., Wang, M., Wang, H., Deng, H., He, T., Tan, Y., Zhu, Z., Wu, Z., Hu, S., & Li, Z. (2017) · Amino Acids · doi:10.1007/s00726-017-2430-5 · Cited by 37
Zheng, J., Merchant, A. T., Wirth, M. D., Zhang, J., Antwi, S. O., Shoaibi, A., Shivappa, N., Stolzenberg‐Solomon, R. Z., Hébert, J. R., & Steck, S. E. (2018) · International Journal of Cancer · doi:10.1002/ijc.31271 · Cited by 39
Chang, J., Tian, J., Zhu, Y., Zhong, R., Zhai, K., Li, J., Ke, J., Han, Q., Lou, J., Chen, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06136-x · Cited by 39
Hmga2 is dispensable for pancreatic cancer development, metastasis, and therapy resistance
Chiou, S., Dorsch, M., Kusch, E., Naranjo, S., Kozak, M. M., Koong, A. C., Winslow, M. M., & Grüner, B. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-32159-x · Cited by 37
Differential methylation landscape of pancreatic ductal adenocarcinoma and its precancerous lesions
Bararia, A., Dey, S., Gulati, S., Ghatak, S., Ghosh, S., Banerjee, S., & Sikdar, N. (2020) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2020.03.010 · Cited by 37
Luongo, M., Marinelli, O., Zeppa, L., Aguzzi, C., Morelli, M. B., Amantini, C., Frassineti, A., di Costanzo, M., Fanelli, A., Santoni, G., et al. (2020) · Cancers · doi:10.3390/cancers12102774 · Cited by 42
Hussung, S., Akhoundova, D., Hipp, J., Follo, M., Klar, R. F. U., Philipp, U., Scherer, F., von Bubnoff, N. C. C., Duyster, J., Boerries, M., et al. (2021) · BMC Cancer · doi:10.1186/s12885-020-07736-x · Cited by 38
He, M., Qiao, Z., Wang, Y., Kuai, Q., Li, C., Wang, Y., Jiang, X., Wang, X., Li, W., He, M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0166896 · Cited by 36
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
Curatolo, A. D., Conciatori, F., Incani, U. C., Bazzichetto, C., Falcone, I., Corbo, V., D’Agosto, S. L., Eramo, A., Sette, G., Sperduti, I., et al. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0820-5 · Cited by 36
Xie, J., Cheng, C., Zhu, X. Y., Shen, Y., Song, L. B., Chen, H., Chen, Z., Liu, L.-M., & Meng, Z. Q. (2019) · Aging · doi:10.18632/aging.101940 · Cited by 37
Epidemiology of HPB malignancy in the elderly
Pericleous, M., & Khan, S. A. (2020) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2020.03.222 · Cited by 38
Pan, M., Jiang, C., Zhang, Z., Achacoso, N. S., Alexeeff, S., Solorzano, A. V., Tse, P., Chung, E. H., Sundaresan, T. K., Suga, J. M., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.22.00570 · Cited by 38
Clinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Park, W., O'Connor, C. A., Bandlamudi, C., Forman, D., Chou, J. F., Umeda, S., Reyngold, M., Varghese, A. M., Keane, F., Balogun, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1483 · Cited by 34
IL-33 acts as a foe to MIA PaCa-2 pancreatic cancer
Fang, Y., Zhao, L., Xiao, H., Cook, K. M., Bai, Q., Herrick, E. J., Chen, X., Qin, C., Zhu, Z., Wakefield, M. R., et al. (2017) · Medical Oncology · doi:10.1007/s12032-016-0880-3 · Cited by 34
Quirin, K. A., Kwon, J. J., Alioufi, A., Factora, T. D., Temm, C. J., Jacobsen, M. H., Sandusky, G. E., Shontz, K., Chicoine, L. G., Clark, K. R., et al. (2017) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2017.09.006 · Cited by 35
Lan, W., Bian, B., Xia, Y., Dou, S., Gayet, O., Bigonnet, M., Santofimia‐Castaño, P., Cong, M., Peng, L., Dusetti, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26613-z · Cited by 34
Bahmani, B., Uehara, M., Ordikhani, F., Li, X., Jiang, L., Banouni, N., Ichimura, T., Kasinath, V., Eskandari, S. K., Annabi, N., et al. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.030 · Cited by 34
Li, H., Wang, P., Gong, W., Wang, Q., Zhou, J., Zhu, W., & Cheng, Y. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700912 · Cited by 33
Smith, S. J., Li, C. M., Lingeman, R. G., Hickey, R. J., Liu, Y., Malkas, L. H., & Raoof, M. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.03.025 · Cited by 33
Role of targeted immunotherapy for pancreatic ductal adenocarcinoma (PDAC) treatment: An overview
Panchal, K., Sahoo, R. K., Gupta, U. D., & Chaurasiya, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107508 · Cited by 33
Carlo, C. D., Sousa, B. C., Manfredi, M., Brandi, J., Pozza, E. D., Marengo, E., Palmieri, M., Dando, I., Wakelam, M. J. O., Lopez‐Clavijo, A. F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-92752-5 · Cited by 35
Huang, F., Peng, J., Cheng, W., Zhuang, Y., Wang, L., Li, C.-Q., Tang, J., Chen, W., Li, Y., & Zhang, S. (2017) · Digestive Diseases and Sciences · doi:10.1007/s10620-017-4472-7 · Cited by 33
Pharmacogenetics of treatments for pancreatic cancer
Hassouni, B. E., Petri, G. L., Liu, D., Cascioferro, S., Parrino, B., Hassan, W. U., Diana, P., Ali, A., Frampton, A. E., & Giovannetti, E. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1620731 · Cited by 34
Ding, J., He, X., Cheng, X., Cao, G., Chen, B., Chen, S., & Xiong, M. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02204-7 · Cited by 32
GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma
Liu, B., Huang, R., Fu, T., He, P., Du, C., Zhou, W., Xu, K., & Ren, T. (2021) · PeerJ · doi:10.7717/peerj.11423 · Cited by 32
Ha, D. P., Huang, B., Wang, H., Rangel, D. F., Krieken, R. V., Liu, Z., Samanta, S., Neamati, N., & Lee, A. S. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100837 · Cited by 33
Saiyin, H., Na, N., Han, X., Fang, Y., Wu, Y., Lou, W., & Yang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.17965 · Cited by 35
Roles of autophagy and metabolism in pancreatic cancer cell adaptation to environmental challenges
Maertin, S., Elperin, J. M., Lotshaw, E. M., Sendler, M., Speakman, S., Takakura, K., Reicher, B., Mareninova, O. A., Grippo, P. J., Mayerle, J. V., et al. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00138.2017 · Cited by 31
Luteolin-regulated MicroRNA-301-3p Targets Caspase-8 and Modulates TRAIL Sensitivity in PANC-1 Cells
Moeng, S., Son, S. W., Seo, H. A., Lee, J. S., Kim, C. K., Kuh, H. J., & Park, J. K. (2020) · Anticancer Research · doi:10.21873/anticanres.14003 · Cited by 31
Oyeneyin, O. E., Obadawo, B. S., Olanrewaju, A. A., Owolabi, T. O., Gbadamosi, F. A., Ipinloju, N., & Modamori, H. O. (2021) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-021-00133-2 · Cited by 31
Huang, C., Xiang, Y., Chen, S., Yu, H., Wen, Z., Ye, T., Sun, H., Kong, H., Li, D., Yu, D., et al. (2017) · Cancer Science · doi:10.1111/cas.13347 · Cited by 30
Bolck, H. A., Pauli, C., Göbel, E., Mühlbauer, K., Dettwiler, S., Moch, H., & Schraml, P. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00246 · Cited by 30
Differential expression of MAGEA6 toggles autophagy to promote pancreatic cancer progression
Tsang, Y. H., Wang, Y., Kong, K., Grzeskowiak, C. L., Zagorodna, O., Dogruluk, T., Lu, H., Villafañe, N., Bhavana, V. H., Moreno, D., et al. (2020) · eLife · doi:10.7554/elife.48963 · Cited by 31
Rozengurt, E., & Eibl, G. (2021) · Cancers · doi:10.3390/cancers13205126 · Cited by 31
Cannone, S., Greco, M. R., Carvalho, T. M. A., Guizouarn, H., Soriani, O., Molfetta, D. D., Tomasini, R., Zeeberg, K., Reshkin, S. J., & Cardone, R. A. (2022) · Cancers · doi:10.3390/cancers14153737 · Cited by 31
Gemcitabine promotes autophagy and lysosomal function through ERK- and TFEB-dependent mechanisms
Marchand, B., Poulin, M.-A., Lawson, C., Tai, L., Jean, S., & Boucher, M. (2023) · Cell Death Discovery · doi:10.1038/s41420-023-01342-z · Cited by 32
Inhibiting stromal Class I HDACs curbs pancreatic cancer progression
Liang, G., Oh, T. G., Hah, N., Tiriac, H., Shi, Y., Truitt, M., Antal, C. E., Atkins, A. R., Li, Y., Fraser, C. R., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42178-6 · Cited by 32
Metadata
- Authors
- Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- ORCID
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-02-15
- Volume
- 30
- Issue
- 4
- Pages
- 355-385
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W4295846302
- Cited by
- 527
- References
- 392
- Citations by year
- 2026: 20 · 2025: 33 · 2024: 44 · 2023: 68 · 2022: 56 · 2021: 75 · 2020: 57 · 2019: 48 · 2018: 51 · 2017: 59 · 2016: 16
- Type
- posted content
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Genes & Development (publishedVersion, cc-by-nc)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Sheikh Ahmed Center for Pancreatic Cancer Research
- Pancreatic Cancer Moon Shot at the University of Texas MD Anderson Cancer Center
- University of Texas Star Award (W81XWH-14-1-0429)
- Department of Defense (U01DK108328, U01CA196403)
- Odyssey Fellowship (Anne Eastland Spears Fellowship in GI Cancer Research)
- University of Texas MD Anderson Cancer Center (RSG-13-298-01-TBG)
- American Cancer Society (R01GM095567, R01CA157490, R01CA188048)
- National Institutes of Health (14-90-25-DRAE, P01CA117969)
- American Association for Cancer Research (W81XWH-11-1-0418)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- pancreatic ductal adenocarcinoma, cancer genomics, molecular classification, cancer metabolism, DNA repair, tumor microenvironment, cancer immunotherapy, drug discovery, obesity, metabolic syndrome, preclinical models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
